Heart Disease in the Acute Hospital

Slides:



Advertisements
Similar presentations
Unstable angina and NSTEMI
Advertisements

Objectives How the heart functions What a heart attack is
Inequalities across Europe in access to primary angioplasty to treat acute heart attack patients -the cross-border dimension- John Martin, MD, FRCP, FESC,
Local improvement following national clinical audit workshops Auditing heart attacks Saving lives Dr Andrew Wragg Barts Health.
Chapter 3 for 12 Lead Training -Precourse-
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Better or bigger: How should we organise emergency care Jon Nicholl School of Health and Related Research University of Sheffield England.
Stroke Mark Sudlow Consultant and Senior Lecturer
PPCI – National Update NCBC Workshop Jim McLenachan, National Clinical Lead for PPCI, NHS Improvement, England. London, 24 th November, NCBC Annual.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Angina and MI.
Primary PCI Treatment of choice for Acute MI.
Supporting NHS Wales to Deliver World Class Healthcare All Wales Stroke Services Improvement Collaborative Learning Session One 21 st October 2009.
Professor Roger Boyle CBE National Director for Heart Disease and Stroke Department of Health PCI in the UK: Fit for service? A view from the Department.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
What are we consulting on?
A modern thrombolysis service is superior to primary angioplasty
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
The impact of pre-hospital thrombolytic treatment on re-infarction rates: Analysis of the Myocardial Infarction National Audit project (MINAP) Dr Simon.
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
1 Primary Angioplasty for Acute STEMI Dr Adam Jacques Dr Sola Odemuyiwa February 2010.
Primary Care Acute Chest Pain Awareness. Background BHF Funded Mid & South West Wales Project –Report from MINAP (Myocardial Ischaemia National Audit.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Myocardial Ischaemia National Audit Project Are we replacing good fibrinolytic treatment with poor primary PCI? John Birkhead who has NO CONFLICT OF INTEREST.
AA 2008 Session III: STEMI The UK data Mark de Belder The James Cook University Hospital Middlesbrough.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Acute Coronary Syndromes SIGN 93. MINAP Mortality after Acute Coronary Syndromes Cumulative: 13.6% Blue 10.6% Green 11.6% Red.
West Hertfordshire Primary Angioplasty Service Masood Khan.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
Acute Coronary Syndromes in West Hertfordshire Masood Khan.
Dr Martyn Thomas Kings College Hospital Primary angioplasty “A UK Experience” “The UK experience”
EMERGENCY MEDICINE in Public Emergency Departments in Kenya Benjamin W. Wachira Dip PEC(SA), MMed EM, FCEM(SA) Emergency Physician.
Acute Myocardial Infarction February 8, 2006.
Blue light to the East of England Heart Attack Centres Dr Sarah Clarke Consultant Cardiologist And Clinical Director Cardiac Services Papworth Hospital.
MINAP: MINAP: Equity of Access in the National Databases in Wales? Swansea University/ABMU, NICOR Swansea University/ABMU,
The ALERT Trial.
Alison Halliday Professor of Vascular Surgery University of Oxford
John P. A. Ioannidis (age 50) Stanford School of Medicine, Athens Graduate, former chairman Department of Hygiene and Epidemiology, University of Ioannina.
Title slide.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
1. Improving stroke care.
Community Education Goal
Danielle Short, BSN, RN, SCRN
HOPE: Heart Outcomes Prevention Evaluation study
Eva Kline-Rogers RN, NP, AACC University of Michigan
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Pravastatin in Elderly Individuals at Risk of Vascular Disease
The IDEAL Study Reference
WOMEN AND HEART DISEASE
RAAS Blockade: Focus on ACEI
Select Topics in Cardiovascular Medicine
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Objectives How the heart functions What a heart attack is
European Heart Association Journal 2007 April
Preventive Angioplasty in Myocardial Infarction Trial
Potential mechanisms whereby statins may reduce the risk of stroke
Primary Care Acute Chest Pain Awareness Project
China PEACE risk estimation tool for in-hospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic.
European Heart Journal Advance Access
Claudio Sandroni a,., Giorgia Ferro a,
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
A Healthy Heart Prior to the session be sure that you have tested your AV equipment and have all of your handouts ready. Welcome participants as they enter.
16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.
Section 6: Update on lipid treatment guidelines
Cardiovascular Epidemiology and Epidemiological Modelling
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Heart Disease in the Acute Hospital Will Orr Consultant Cardiologist

Will Orr Consultant Cardiologist Primary Angioplasty to Improve Heart Attack Survival - The importance of joined-up care for our patients Will Orr Consultant Cardiologist

What is a heart attack?

approx 20% of all UK deaths

30% of all male premature deaths

22% of all female premature deaths

half of all deaths occur before reaching hospital

…but there is some good news of those who survive the initial heart attack: 75% alive at 5 years 67% alive at 10 years (and walking for 30 mins every day halves your risk of having a first or another heart attack)

Improving outcomes for heart attack

CVD Death rates

How do we treat heart attack? thrombolysis (clot-busting drugs)

Absolute mortality reduction per 1000 Pre-Hospital Thrombolysis Boersma et al : Lancet 1996; 348:771-775 Absolute mortality reduction per 1000 treated patients 80 60 40 20 3 6 9 12 15 18 21 24 Treatment delay (h) Early thrombolysis

How good have we been at treating heart attack historically?

Why did we need to change what we were doing? Keely. Lancet 2003;361:13-20 % mortality Primary Angioplasty Thrombolysis heart attack mortality 1 additional life saved for every 44 patients treated with PPCI 25% reduction in mortality

UK Primary PCI October 2008

How important is time? 60 minute Isochrones Oxford & Southampton

How important is time? CTB Time In-hospital 30 days 1 year % Mortality in NIAP CTB Time In-hospital 30 days 1 year 60-120 minutes 2.7 2.9 5.1 120-180 minutes 4.5 4.9 8.7 % increase in mortality at 120-180 mins 67% 69% 71% National Infarct Angioplasty Project. DOH October 2008

How is mortality affected by delay? % Mortality in NIAP CTB Time In-hospital 30 days 1 year 60-120 minutes 2.7 2.9 5.1 120-180 minutes 4.5 4.9 8.7 Greater than 180 minutes 11.4 12.2 15.9 % increase in mortality at 120-180 minutes 67% 69% 71% % increase in mortality at >180 minutes 320% 212% NIAP 2008. www.dh.gov.uk/publications

How is mortality affected by delay? % Mortality in NIAP NIAP 2008. www.dh.gov.uk/publications

How is mortality affected by delay? % Mortality in NIAP CTB Time In-hospital 30 days 1 year 60-120 minutes 2.7 2.9 5.1 120-180 minutes 4.5 4.9 8.7 Greater than 180 minutes 11.4 12.2 15.9 % increase in mortality at 120-180 minutes 67% 69% 71% % increase in mortality at >180 minutes 320% 212% NIAP 2008. www.dh.gov.uk/publications

Primary Angioplasty for ST-elevation MI MINAP RBH % CTB 150 mins % CTB 120 mins n Eng 2009 38 78 83 2010 144 79 96 2011 147 81 95 59 89 2012 166 62 90 2013 186 82 99 60 2014 150 94 2015 92* MINAP = Myocardial Ischaemia National Audit Project, RBH = Royal Berkshire Hospital, CTB = Call-to-Balloon time

How is mortality affected by delay? % Mortality in NIAP if 111 don’t pass the call on to SCAS for 10’, the chances of the patient dying increase by 10% if the paramedic doesn’t pre-alert when the diagnostic ECG is done, but waits until they’re en route 20’ later, the chances of the patient dying may increase by 20% if the team don’t recognise a STEMI, or the Cardiologist blocks the decision to activate the PPCI team out-of-hours, and this doesn’t happen until arrival at hospital, there may be a 30’ delay & a 30% increased risk of dying NNT to save 1 life = 50  SCAS-RBH Heart Attack Team saves an additional 4 lives per year Risk of Death increases by 1% per minute delay

monthly MINAP Audit meeting

Out-of-Hospital Cardiac Arrest (OOHCA) OHCA Oct 2012 – May 2015 OOHCA Survival to Discharge n % England 79618 6672 8.4 South Central Ambulance Service 3428 595 17.4* Royal Berkshire Hospital 493 96 19.5* ** *p<0.001 v England **p=ns v SCAS MINAP data for SCAS & RBH

Summary Primary Angioplasty saves lives and prevents long-term disability if it is done well The quality & effectiveness of Primary Angioplasty is dependent on ALL members of the Heart Attack Team consistently doing their job well and constantly seeking further improvement The faster it is done, the more likely that the patient will survive, and survive without disability

Walking briskly for 30 mins on 5 days of the week halves your risk of heart attack, stroke or death

medicines make an important difference too

Statins

IT’S YOUR CHOICE!! Patients with known vascular disease Lancet 8th Sept 2016 Patients with known vascular disease prevent 1 heart attack/stroke/death for every 10 treated Patients at risk of developing vascular disease - prevent 1 heart attack/stroke/death for every 20 treated Side Effects in 10 000 patients treated for 5 years true muscle inflammation in 5 patients (0.05%) (reversible) muscle aches/weakness in 50 – 100 patients (0.5 – 1%) new diabetes in 50 – 100 patients (0.5 – 1%) haemorrhagic stroke 5 - 10 patients (0.05 – 0.1%) IT’S YOUR CHOICE!!

Statins stabilise plaques lipid core STATIN THERAPY Many individuals who develop vascular disease do not have particularly elevated cholesterol Trials have demonstrated statin benefits on increased regression and reduced progression of atheromatous plaques Meta analysis of 14 trials has shown a 19% reduction in progression of plaques with statins. LDL Targets significantly lower to achieve favourable plaque modulation (LDL reduction >45%) Statins stabilise plaques lipid core

Conclusions Heart Disease remains Britain’s biggest killer Rates of survival without long-term disability continue to improve year-on-year Our emergency treatment of heart disease is the best in the world (especially locally!) Prevention is the best option